HIL CEO and Dr. Morry Blumenfeld live on TV, at OurCrowd’s Global Investor Summit HIL’s CEO Mr. Sagi Brink-Danan, and Dr. Morry Blumenfeld, Venture Partner and Chairman of the Medical Advisory Board at OurCrowd, participated in a discussion livestreamed from …
Continue reading »HIL makes cover of The Marker Bio Magazine on International Women’s Day HIL is featured in the cover story of The Marker’s Bio Magzine’s special edition for International Women’s Day. The issue is dedicated to the subject of Women’s Health, …
Continue reading »Dr. Raphaël Van Roermund joins HIL’s R&D team Dr. Van Roermund, holding a PhD in quantum physics, is an expert in proton beam transport, dose delivery systems and dosimetry. Raphael comes to HIL following 8 years at IBA, the world …
Continue reading »HIL to Participate in IIA’s China Roadshow HIL was invited to partake in Israel Innovation Authority’s (IIA) and Israeli Export Institution’s delegation to China, in affiliation with CSTEC (China Science and Technology Exchange Center). Following a multi-stage competitive process – …
Continue reading »The Nobel Prize in Physics, and an interview with HIL’s Founder & CTO Prof. Zigler This year’s Nobel Physics Prize was awarded in part to Gérard Mourou and Donna Strickland – developers of the revolutionary CPA (Chirped Pulse Amplification) technique, a …
Continue reading »Dr. Moti Botton-Dascal of the Hebrew University of Jerusalem joins HIL’s R&D team Dr. Botton-Dascal is a theoretician in plasma physics specialising in the interaction between radiation and matter. He has over 30 years’ experience in developing models and sophisticated …
Continue reading »HIL is selected as a Silicon70 2018 Company HIL was selected as one of the 70 featured companies in Silicon70 2018, Silicon Review magazine’s annual issue highlighting leading startups. In the feature, HIL’s CEO, Mr. Sagi Brink-Danan, shared the inspiration …
Continue reading »HIL is awarded the Horizon 2020 Seal of Excellence The European Commission managing Horizon 2020 – the EU Framework Programme for Research and Innovation – evaluated HIL’s Phase-II proposal as a high-quality project as part of its highly competitive evaluation process. This means …
Continue reading »HIL Co-Founder and CTO, Prof. Arie Zigler, announced as a finalist for Berthold Leibinger Innovationspreis 2018 Prof. Arie Zigler, HIL’s Co-Founder and CTO, was announced as a finalist for the Berthold Leibinger Innovationspreis of 2018. Professor Zigler was chosen as …
Continue reading »HIL Featured in The Marker Magazine In its special issue for the 2018 MIXiii Biomed Conference and Exhibition, The Marker Magazine tells the story of HIL and its unique Proton Therapy solution. HIL’s CEO Mr. Sagi Brink-Danan shared our vision and his own …
Continue reading »